EcoRub (”EcoRub” eller ”bolaget”) publicerade den 12 maj 2025 bolagets delårsrapport för det första ...
EQL Pharma presterar starkt och visar upp en väl tilltagen omsättningstillväxt i kombination med god...
VibroSense redovisade en nettoomsättning om 0,75 MSEK (0,47) i kvartalet, vilket var en ökning med 5...
BIovica has entered a reference lab agreement with Tempus a US listed company.
Redeye has interviewed Pia Renaudin, CEO at Scibase, in connection with the Q1 report.
Den 12 maj 2025 meddelade AcuCort (”AcuCort” eller ”Bolaget”) att Bolaget mottagit en ny order på Ze...
ByggPartnerGruppen levererade en stark rapport där orderingången närapå dubblades.
Redeye comments on IRLAB’s announcement of extended U.
Redeye states CoinShares surpassed its EBITDA expectations by 14%, primarily due to the CSCM segment...
Relais reported Q1 adjusted EBITA of EUR 9.2m was down 5% y/y, in line with LSEG Data & Analytics co...
Net sales of SEK67.7m were almost SEK9m higher than expected.
Redeye has updated its near-term estimates and valuation following the Q1 report.
Net sales were in line with our expectation for Q1, with adjusted EBITA as much as 8% (EUR 0.
Q1 likely solid, Q2 comments on activity in focus We expect FY guidance to be reiterated EBITA -3-4%...
Stabilt, stabilare, EQL Pharma Nettoomsättningen ökade med imponerande 45,0 %, främst drivet av tidi...
Orders and sales below consensus in Q1, costs above Optimistic H2'25 guidance reiterated, we cut EBI...
Nettoomsättningen uppgick till 204,6 MSEK (199,3), vilket motsvarade en ökning med 2,7% y-o-y.
Redeye strengthens its positive view of CombinedX after acquiring the IFS partner Align.
Redeye thinks the new positive MAD results from CAN10 further support the case.
Telko and Leipurin segments both reported EUR 0.3m higher adjusted EBITA than we forecasted in Q1.
